nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Risedronate—PTGS2—muscle cancer	0.0167	1	CrCbGaD
Ibandronate—FDPS—smooth muscle tissue—muscle cancer	0.00301	0.16	CbGeAlD
Ibandronate—Urethral disorder—Etoposide—muscle cancer	0.00294	0.00305	CcSEcCtD
Ibandronate—Infection—Dactinomycin—muscle cancer	0.00292	0.00303	CcSEcCtD
Ibandronate—Vaginal infection—Doxorubicin—muscle cancer	0.00292	0.00303	CcSEcCtD
Ibandronate—FDPS—renal system—muscle cancer	0.0029	0.154	CbGeAlD
Ibandronate—Vertigo—Vincristine—muscle cancer	0.00289	0.003	CcSEcCtD
Ibandronate—Oesophagitis—Doxorubicin—muscle cancer	0.00283	0.00293	CcSEcCtD
Ibandronate—Renal failure acute—Methotrexate—muscle cancer	0.00281	0.00291	CcSEcCtD
Ibandronate—Eye disorder—Etoposide—muscle cancer	0.0028	0.0029	CcSEcCtD
Ibandronate—Ecchymosis—Doxorubicin—muscle cancer	0.0028	0.0029	CcSEcCtD
Ibandronate—Bladder pain—Doxorubicin—muscle cancer	0.0028	0.0029	CcSEcCtD
Ibandronate—Mouth ulceration—Doxorubicin—muscle cancer	0.0028	0.0029	CcSEcCtD
Ibandronate—Cardiac disorder—Etoposide—muscle cancer	0.00278	0.00288	CcSEcCtD
Ibandronate—Hypertension—Vincristine—muscle cancer	0.00278	0.00288	CcSEcCtD
Ibandronate—Pulmonary oedema—Doxorubicin—muscle cancer	0.00276	0.00286	CcSEcCtD
Ibandronate—Myalgia—Vincristine—muscle cancer	0.00274	0.00284	CcSEcCtD
Ibandronate—Angiopathy—Etoposide—muscle cancer	0.00272	0.00282	CcSEcCtD
Ibandronate—Hypertonia—Doxorubicin—muscle cancer	0.00271	0.00281	CcSEcCtD
Ibandronate—Immune system disorder—Etoposide—muscle cancer	0.00271	0.00281	CcSEcCtD
Ibandronate—Mediastinal disorder—Etoposide—muscle cancer	0.0027	0.0028	CcSEcCtD
Ibandronate—Chills—Etoposide—muscle cancer	0.00269	0.00279	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00268	0.00278	CcSEcCtD
Ibandronate—Alopecia—Etoposide—muscle cancer	0.00265	0.00275	CcSEcCtD
Ibandronate—Anaphylactic shock—Vincristine—muscle cancer	0.00263	0.00273	CcSEcCtD
Ibandronate—Infection—Vincristine—muscle cancer	0.00261	0.00271	CcSEcCtD
Ibandronate—Osteoarthritis—Methotrexate—muscle cancer	0.0026	0.00269	CcSEcCtD
Ibandronate—FDPS—cardiac atrium—muscle cancer	0.00259	0.138	CbGeAlD
Ibandronate—Nervous system disorder—Vincristine—muscle cancer	0.00258	0.00267	CcSEcCtD
Ibandronate—Decreased appetite—Dactinomycin—muscle cancer	0.00256	0.00265	CcSEcCtD
Ibandronate—Dysgeusia—Etoposide—muscle cancer	0.00255	0.00265	CcSEcCtD
Ibandronate—Hyperhidrosis—Vincristine—muscle cancer	0.00254	0.00263	CcSEcCtD
Ibandronate—Fatigue—Dactinomycin—muscle cancer	0.00254	0.00263	CcSEcCtD
Ibandronate—Back pain—Etoposide—muscle cancer	0.00252	0.00262	CcSEcCtD
Ibandronate—Pain—Dactinomycin—muscle cancer	0.00252	0.00261	CcSEcCtD
Ibandronate—Muscle spasms—Etoposide—muscle cancer	0.00251	0.0026	CcSEcCtD
Ibandronate—Renal failure acute—Doxorubicin—muscle cancer	0.00243	0.00252	CcSEcCtD
Ibandronate—Feeling abnormal—Dactinomycin—muscle cancer	0.00242	0.00251	CcSEcCtD
Ibandronate—Ill-defined disorder—Etoposide—muscle cancer	0.00242	0.00251	CcSEcCtD
Ibandronate—Anaemia—Etoposide—muscle cancer	0.00241	0.0025	CcSEcCtD
Ibandronate—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00241	0.00249	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00239	0.00248	CcSEcCtD
Ibandronate—Insomnia—Vincristine—muscle cancer	0.00238	0.00247	CcSEcCtD
Ibandronate—Renal impairment—Doxorubicin—muscle cancer	0.00236	0.00245	CcSEcCtD
Ibandronate—Paraesthesia—Vincristine—muscle cancer	0.00236	0.00245	CcSEcCtD
Ibandronate—Malaise—Etoposide—muscle cancer	0.00235	0.00244	CcSEcCtD
Ibandronate—Breast disorder—Methotrexate—muscle cancer	0.00235	0.00243	CcSEcCtD
Ibandronate—Vertigo—Etoposide—muscle cancer	0.00234	0.00243	CcSEcCtD
Ibandronate—Abdominal pain—Dactinomycin—muscle cancer	0.00233	0.00241	CcSEcCtD
Ibandronate—Body temperature increased—Dactinomycin—muscle cancer	0.00233	0.00241	CcSEcCtD
Ibandronate—Decreased appetite—Vincristine—muscle cancer	0.00229	0.00237	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Vincristine—muscle cancer	0.00227	0.00235	CcSEcCtD
Ibandronate—Fatigue—Vincristine—muscle cancer	0.00227	0.00235	CcSEcCtD
Ibandronate—FDPS—tendon—muscle cancer	0.00226	0.12	CbGeAlD
Ibandronate—Hypertension—Etoposide—muscle cancer	0.00225	0.00234	CcSEcCtD
Ibandronate—Pain—Vincristine—muscle cancer	0.00225	0.00233	CcSEcCtD
Ibandronate—Constipation—Vincristine—muscle cancer	0.00225	0.00233	CcSEcCtD
Ibandronate—Osteoarthritis—Doxorubicin—muscle cancer	0.00225	0.00233	CcSEcCtD
Ibandronate—Pain in extremity—Doxorubicin—muscle cancer	0.00225	0.00233	CcSEcCtD
Ibandronate—Asthma—Methotrexate—muscle cancer	0.00224	0.00233	CcSEcCtD
Ibandronate—Chest pain—Etoposide—muscle cancer	0.00222	0.0023	CcSEcCtD
Ibandronate—Migraine—Doxorubicin—muscle cancer	0.00221	0.00229	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00221	0.00229	CcSEcCtD
Ibandronate—Discomfort—Etoposide—muscle cancer	0.00219	0.00228	CcSEcCtD
Ibandronate—FDPS—bone marrow—muscle cancer	0.00219	0.116	CbGeAlD
Ibandronate—Face oedema—Doxorubicin—muscle cancer	0.00217	0.00225	CcSEcCtD
Ibandronate—Hypersensitivity—Dactinomycin—muscle cancer	0.00217	0.00225	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—muscle cancer	0.00215	0.00223	CcSEcCtD
Ibandronate—Gastrointestinal pain—Vincristine—muscle cancer	0.00215	0.00223	CcSEcCtD
Ibandronate—Anaphylactic shock—Etoposide—muscle cancer	0.00213	0.00221	CcSEcCtD
Ibandronate—Infection—Etoposide—muscle cancer	0.00212	0.00219	CcSEcCtD
Ibandronate—Asthenia—Dactinomycin—muscle cancer	0.00211	0.00219	CcSEcCtD
Ibandronate—Blood creatinine increased—Doxorubicin—muscle cancer	0.00211	0.00218	CcSEcCtD
Ibandronate—FDPS—vagina—muscle cancer	0.0021	0.111	CbGeAlD
Ibandronate—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00208	0.00216	CcSEcCtD
Ibandronate—Abdominal pain—Vincristine—muscle cancer	0.00208	0.00215	CcSEcCtD
Ibandronate—Body temperature increased—Vincristine—muscle cancer	0.00208	0.00215	CcSEcCtD
Ibandronate—Skin disorder—Etoposide—muscle cancer	0.00207	0.00214	CcSEcCtD
Ibandronate—Hyperhidrosis—Etoposide—muscle cancer	0.00206	0.00213	CcSEcCtD
Ibandronate—Abdominal pain upper—Doxorubicin—muscle cancer	0.00205	0.00213	CcSEcCtD
Ibandronate—Breast disorder—Doxorubicin—muscle cancer	0.00203	0.00211	CcSEcCtD
Ibandronate—Diarrhoea—Dactinomycin—muscle cancer	0.00201	0.00209	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—muscle cancer	0.00201	0.00209	CcSEcCtD
Ibandronate—Nasopharyngitis—Doxorubicin—muscle cancer	0.00201	0.00208	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—muscle cancer	0.002	0.00207	CcSEcCtD
Ibandronate—Infestation—Methotrexate—muscle cancer	0.002	0.00207	CcSEcCtD
Ibandronate—Depression—Methotrexate—muscle cancer	0.00199	0.00207	CcSEcCtD
Ibandronate—Gastritis—Doxorubicin—muscle cancer	0.00199	0.00206	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—muscle cancer	0.00197	0.00204	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—muscle cancer	0.00195	0.00202	CcSEcCtD
Ibandronate—Dysphagia—Doxorubicin—muscle cancer	0.00194	0.00201	CcSEcCtD
Ibandronate—Influenza—Doxorubicin—muscle cancer	0.00194	0.00201	CcSEcCtD
Ibandronate—Asthma—Doxorubicin—muscle cancer	0.00194	0.00201	CcSEcCtD
Ibandronate—FDPS—head—muscle cancer	0.00194	0.103	CbGeAlD
Ibandronate—Hypersensitivity—Vincristine—muscle cancer	0.00194	0.00201	CcSEcCtD
Ibandronate—Sweating—Methotrexate—muscle cancer	0.00192	0.00199	CcSEcCtD
Ibandronate—Paraesthesia—Etoposide—muscle cancer	0.00191	0.00198	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—muscle cancer	0.00189	0.00196	CcSEcCtD
Ibandronate—Asthenia—Vincristine—muscle cancer	0.00189	0.00196	CcSEcCtD
Ibandronate—FDPS—testis—muscle cancer	0.00187	0.0993	CbGeAlD
Ibandronate—Vomiting—Dactinomycin—muscle cancer	0.00187	0.00194	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—muscle cancer	0.00187	0.00194	CcSEcCtD
Ibandronate—Rash—Dactinomycin—muscle cancer	0.00186	0.00192	CcSEcCtD
Ibandronate—Decreased appetite—Etoposide—muscle cancer	0.00185	0.00192	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Etoposide—muscle cancer	0.00184	0.00191	CcSEcCtD
Ibandronate—Fatigue—Etoposide—muscle cancer	0.00184	0.0019	CcSEcCtD
Ibandronate—Pain—Etoposide—muscle cancer	0.00182	0.00189	CcSEcCtD
Ibandronate—Constipation—Etoposide—muscle cancer	0.00182	0.00189	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.0018	0.00187	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—muscle cancer	0.0018	0.00187	CcSEcCtD
Ibandronate—Diarrhoea—Vincristine—muscle cancer	0.0018	0.00186	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—muscle cancer	0.0018	0.00186	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—muscle cancer	0.00178	0.00185	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—muscle cancer	0.00177	0.00184	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—muscle cancer	0.00176	0.00182	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—muscle cancer	0.00176	0.00182	CcSEcCtD
Ibandronate—Feeling abnormal—Etoposide—muscle cancer	0.00175	0.00182	CcSEcCtD
Ibandronate—Nausea—Dactinomycin—muscle cancer	0.00175	0.00181	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—muscle cancer	0.00174	0.00181	CcSEcCtD
Ibandronate—Gastrointestinal pain—Etoposide—muscle cancer	0.00174	0.00181	CcSEcCtD
Ibandronate—Dizziness—Vincristine—muscle cancer	0.00174	0.0018	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—muscle cancer	0.00173	0.0018	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—muscle cancer	0.00173	0.0018	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—muscle cancer	0.0017	0.00176	CcSEcCtD
Ibandronate—Urticaria—Etoposide—muscle cancer	0.00169	0.00175	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—muscle cancer	0.00169	0.00175	CcSEcCtD
Ibandronate—Abdominal pain—Etoposide—muscle cancer	0.00168	0.00175	CcSEcCtD
Ibandronate—Body temperature increased—Etoposide—muscle cancer	0.00168	0.00175	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—muscle cancer	0.00168	0.00175	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—muscle cancer	0.00168	0.00174	CcSEcCtD
Ibandronate—Vomiting—Vincristine—muscle cancer	0.00167	0.00173	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—muscle cancer	0.00167	0.00173	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—muscle cancer	0.00166	0.00172	CcSEcCtD
Ibandronate—Rash—Vincristine—muscle cancer	0.00166	0.00172	CcSEcCtD
Ibandronate—Dermatitis—Vincristine—muscle cancer	0.00166	0.00172	CcSEcCtD
Ibandronate—Headache—Vincristine—muscle cancer	0.00165	0.00171	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00164	0.0017	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—muscle cancer	0.00163	0.00169	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—muscle cancer	0.00162	0.00168	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—muscle cancer	0.00162	0.00168	CcSEcCtD
Ibandronate—Chills—Methotrexate—muscle cancer	0.00161	0.00167	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—muscle cancer	0.00159	0.00164	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—muscle cancer	0.00157	0.00163	CcSEcCtD
Ibandronate—Hypersensitivity—Etoposide—muscle cancer	0.00157	0.00163	CcSEcCtD
Ibandronate—Erythema—Methotrexate—muscle cancer	0.00156	0.00162	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—muscle cancer	0.00156	0.00162	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—muscle cancer	0.00156	0.00162	CcSEcCtD
Ibandronate—Nausea—Vincristine—muscle cancer	0.00156	0.00162	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—muscle cancer	0.00155	0.00161	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—muscle cancer	0.00154	0.0016	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—muscle cancer	0.00154	0.00159	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—muscle cancer	0.00153	0.00159	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—muscle cancer	0.00153	0.00159	CcSEcCtD
Ibandronate—Asthenia—Etoposide—muscle cancer	0.00153	0.00158	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—muscle cancer	0.00153	0.00158	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—muscle cancer	0.00152	0.00158	CcSEcCtD
Ibandronate—Back pain—Methotrexate—muscle cancer	0.00151	0.00157	CcSEcCtD
Ibandronate—Pruritus—Etoposide—muscle cancer	0.00151	0.00156	CcSEcCtD
Ibandronate—Diarrhoea—Etoposide—muscle cancer	0.00146	0.00151	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—muscle cancer	0.00145	0.00151	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—muscle cancer	0.00145	0.0015	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—muscle cancer	0.00144	0.0015	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—muscle cancer	0.00144	0.0015	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—muscle cancer	0.00141	0.00146	CcSEcCtD
Ibandronate—Malaise—Methotrexate—muscle cancer	0.00141	0.00146	CcSEcCtD
Ibandronate—Dizziness—Etoposide—muscle cancer	0.00141	0.00146	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—muscle cancer	0.0014	0.00146	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—muscle cancer	0.0014	0.00146	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—muscle cancer	0.0014	0.00145	CcSEcCtD
Ibandronate—Chills—Doxorubicin—muscle cancer	0.00139	0.00145	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—muscle cancer	0.00137	0.00142	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—muscle cancer	0.00136	0.00141	CcSEcCtD
Ibandronate—Vomiting—Etoposide—muscle cancer	0.00135	0.0014	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—muscle cancer	0.00135	0.0014	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—muscle cancer	0.00135	0.0014	CcSEcCtD
Ibandronate—Rash—Etoposide—muscle cancer	0.00134	0.00139	CcSEcCtD
Ibandronate—Dermatitis—Etoposide—muscle cancer	0.00134	0.00139	CcSEcCtD
Ibandronate—Headache—Etoposide—muscle cancer	0.00133	0.00138	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—muscle cancer	0.00133	0.00138	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—muscle cancer	0.00133	0.00138	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—muscle cancer	0.00133	0.00138	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—muscle cancer	0.00133	0.00138	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—muscle cancer	0.00133	0.00137	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00132	0.00137	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—muscle cancer	0.00131	0.00136	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—muscle cancer	0.00131	0.00136	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—muscle cancer	0.0013	0.00135	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—muscle cancer	0.00128	0.00132	CcSEcCtD
Ibandronate—Infection—Methotrexate—muscle cancer	0.00127	0.00131	CcSEcCtD
Ibandronate—Nausea—Etoposide—muscle cancer	0.00126	0.00131	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—muscle cancer	0.00126	0.0013	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—muscle cancer	0.00125	0.0013	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—muscle cancer	0.00125	0.0013	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—muscle cancer	0.00124	0.00128	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—muscle cancer	0.00123	0.00128	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—muscle cancer	0.00122	0.00127	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—muscle cancer	0.00122	0.00126	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—muscle cancer	0.0012	0.00124	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—muscle cancer	0.00117	0.00121	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00116	0.0012	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—muscle cancer	0.00115	0.0012	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—muscle cancer	0.00115	0.00119	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—muscle cancer	0.00115	0.00119	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—muscle cancer	0.00115	0.00119	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—muscle cancer	0.00115	0.00119	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—muscle cancer	0.00115	0.00119	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00114	0.00119	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—muscle cancer	0.00114	0.00118	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—muscle cancer	0.00113	0.00117	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—muscle cancer	0.00112	0.00116	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—muscle cancer	0.00111	0.00115	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—muscle cancer	0.0011	0.00115	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—muscle cancer	0.0011	0.00114	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—muscle cancer	0.0011	0.00114	CcSEcCtD
Ibandronate—Infection—Doxorubicin—muscle cancer	0.0011	0.00114	CcSEcCtD
Ibandronate—Pain—Methotrexate—muscle cancer	0.00109	0.00113	CcSEcCtD
Ibandronate—Shock—Doxorubicin—muscle cancer	0.00109	0.00113	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—muscle cancer	0.00108	0.00112	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—muscle cancer	0.00107	0.00111	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—muscle cancer	0.00107	0.00111	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—muscle cancer	0.00105	0.00109	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—muscle cancer	0.00104	0.00108	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—muscle cancer	0.00101	0.00105	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—muscle cancer	0.00101	0.00105	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—muscle cancer	0.00101	0.00105	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00101	0.00104	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—muscle cancer	0.000999	0.00104	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—muscle cancer	0.000992	0.00103	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—muscle cancer	0.000972	0.00101	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—muscle cancer	0.00096	0.000995	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000953	0.000989	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—muscle cancer	0.000952	0.000987	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—muscle cancer	0.000944	0.000979	CcSEcCtD
Ibandronate—Pain—Doxorubicin—muscle cancer	0.000944	0.000979	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—muscle cancer	0.00094	0.000974	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—muscle cancer	0.000915	0.000949	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—muscle cancer	0.00091	0.000944	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000903	0.000936	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—muscle cancer	0.000902	0.000936	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—muscle cancer	0.000877	0.00091	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—muscle cancer	0.000873	0.000905	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—muscle cancer	0.000873	0.000905	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—muscle cancer	0.000873	0.000905	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—muscle cancer	0.000843	0.000874	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—muscle cancer	0.000814	0.000844	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—muscle cancer	0.000811	0.000841	CcSEcCtD
Ibandronate—Rash—Methotrexate—muscle cancer	0.000804	0.000834	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—muscle cancer	0.000803	0.000833	CcSEcCtD
Ibandronate—Headache—Methotrexate—muscle cancer	0.000799	0.000828	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—muscle cancer	0.000792	0.000822	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—muscle cancer	0.000781	0.00081	CcSEcCtD
Ibandronate—Nausea—Methotrexate—muscle cancer	0.000758	0.000786	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—muscle cancer	0.000756	0.000783	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—muscle cancer	0.00073	0.000757	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—muscle cancer	0.000702	0.000728	CcSEcCtD
Ibandronate—Rash—Doxorubicin—muscle cancer	0.000696	0.000722	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—muscle cancer	0.000696	0.000721	CcSEcCtD
Ibandronate—Headache—Doxorubicin—muscle cancer	0.000692	0.000717	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—muscle cancer	0.000656	0.00068	CcSEcCtD
